Education
About Us
Working with TipRanks
Follow Us
Integrum AB Class B (DE:6Y1)
FRANKFURT:6Y1
6Y1 Stock Chart & Stats
€0.94
-€0.06(-3.43%)
At close: 4:00 PM EST
€0.94
-€0.06(-3.43%)
Day’s Range― - ―
52-Week Range€0.68 - €3.86
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€19.67M
Enterprise Value€173.07M
Total Cash (Recent Filing)€7.77M
Total Debt (Recent Filing)€4.02M
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Mar 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding26,027,910
10 Day Avg. Volume6
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.64
Price to Sales (P/S)3.20
P/FCF Ratio-5.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth (TTM +58.1% and Fundamentals ~62% growth) indicates expanding clinical adoption of OPRA and stronger market penetration. Over 2–6 months this trend supports scale economies, stronger negotiating leverage with clinics, and a larger installed base for recurring parts sales.
Conservative Capital StructureA low leverage profile and healthy equity ratio reduce solvency risk and preserve financial flexibility. This durable strength supports funding regulatory, clinical and commercial initiatives without heavy interest burden, enabling strategic investments and resilience through reimbursement cycles.
Proprietary Niche Product & Recurring RevenueA specialized, proprietary osseointegration system marketed to clinical centers creates a defensible niche and recurring revenue from implants, consumable parts and follow-up services. This business model fosters long-term customer relationships and predictable lifelong spending per patient.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flows signal cash burn from operations, limiting ability to self-fund expansion or clinical rollout. Even with slight FCF improvement, continued cash deficits increase reliance on external financing and constrain long-term investment pacing.
Unprofitable Operations / Margin PressureStrong gross margins paired with negative EBIT and net profit point to elevated operating costs—commercial, regulatory or administrative—that erode profitability. Unless operating efficiencies or scale reduce overhead, sustained margin weakness threatens long-term return generation for shareholders.
Limited Organizational ScaleA small employee base (36) constrains capacity for broad commercial rollouts, regulatory submissions, and post‑op support across multiple markets. This limited scale can slow adoption, increase dependence on partners/centers, and create execution risk as demand and complexity grow.
Integrum AB Class B News
6Y1 FAQ
What was Integrum AB Class B’s price range in the past 12 months?
Integrum AB Class B lowest stock price was €0.68 and its highest was €3.86 in the past 12 months.
What is Integrum AB Class B’s market cap?
Integrum AB Class B’s market cap is €19.67M.
When is Integrum AB Class B’s upcoming earnings report date?
Integrum AB Class B’s upcoming earnings report date is Mar 02, 2026 which is in 10 days.
How were Integrum AB Class B’s earnings last quarter?
Integrum AB Class B released its earnings results on Nov 21, 2025. The company reported -€0.032 earnings per share for the quarter, missing the consensus estimate of -€0.002 by -€0.03.
Is Integrum AB Class B overvalued?
According to Wall Street analysts Integrum AB Class B’s price is currently Overvalued.
Does Integrum AB Class B pay dividends?
Integrum AB Class B does not currently pay dividends.
What is Integrum AB Class B’s EPS estimate?
Integrum AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrum AB Class B have?
Integrum AB Class B has 26,027,910 shares outstanding.
What happened to Integrum AB Class B’s price movement after its last earnings report?
Integrum AB Class B reported an EPS of -€0.032 in its last earnings report, missing expectations of -€0.002. Following the earnings report the stock price went down -0.135%.
Which hedge fund is a major shareholder of Integrum AB Class B?
Currently, no hedge funds are holding shares in DE:6Y1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrum AB Class B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. The company also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was founded in 1962 and is headquartered in Mölndal, Sweden.